Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 10/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068421 | 0.89 | CACNA1H (0.39) | CACNA1HEPHX1DRD2SIGMAR1 | |
| SCHEMBL25755480 | 0.85 | DRD2 (0.40) | CACNA1HEPHX1DRD2TDP1SIGMAR1 | |
| SCHEMBL25755605 | 0.83 | DRD2 (0.42) | MEN1GAAKMT2ACACNA1HEPHX1 | |
| SCHEMBL23765870 | 0.77 | CACNA1H (0.47) | CACNA1HEPHX1DRD2TDP1SIGMAR1 | |
| SCHEMBL31305414 | 0.77 | DRD2 (0.50) | CACNA1HDRD2TDP1SIGMAR1 | |
| SCHEMBL25755571 | 0.77 | DRD2 (0.48) | MEN1GAAKMT2ACACNA1HEPHX1 | |
| SCHEMBL25755376 | 0.75 | — | — | |
| SCHEMBL13021104 | 0.75 | DRD2 (0.46) | CACNA1HDRD2TDP1SIGMAR1 | |
| SCHEMBL13612357 | 0.74 | TDP1 (0.44) | MEN1GAAKMT2AEPHX1TDP1 | |
| SCHEMBL25755386 | 0.74 | LTA4H (0.34) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| EP-4134104-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | MEN1 940/4885GAA 520/4885KMT2A 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.